An Aimmune Therapeutics drug developed to treat peanut allergy won FDA approval late Friday—the first time the agency has approved an oral immunotherapy for a food allergy.
The Aimmune (NASDAQ: AIMT) drug, Palforzia, was developed to desensitize patients to peanuts. The FDA decision covers patients between the ages of 4 and 17 who have a confirmed peanut allergy diagnosis. Brisbane, CA-based Aimmune says it expects the drug will become available to patients in coming weeks.
Palforzia is a powder made from peanut flour that comes in capsules or packets. Aimmune developed its therapy so that each dose contains precise… Read more »
UNDERWRITERS AND PARTNERS
